Recombinant Human APLN Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02733P-100UG
Human APLN on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human APLN Protein, Active
Beta LifeScience
SKU/CAT #: BLK-02733P-100UG
Collections: Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human APLN Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Gly23-Phe77. |
Purity | > 95% as determined by Tris-Bis PAGE |
Accession | Q9ULZ1 |
Target Symbol | APLN |
Synonyms | Apelin;APJ endogenous ligand;APEL |
Species | Human |
Expression System | HEK293 |
Tag | C-hFc |
Expression Range | Gly23-Phe77 |
Mol. Weight | The protein has a predicted MW of 32.9 kDa. Due to glycosylation, the protein migrates to 35-40 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS, 200mM Arginine (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human APLN, hFc Tag at 0.5ug/ml (100ul/Well) on the plate. Dose response curve for Biotinylated Anti-APLN Antibody, hFc Tag with the EC50 of 22.2ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | Macrophages play key roles during cardiovascular diseases (CVD) and their related complications.Apelin (APLN) is a key molecule, whose roles during CVD have been documented previously. Therefore, it has been hypothesized that APLN may perform its roles via modulation of macrophages. Additionally, due to the widespread distribution of the CVD, more effective therapeutic strategies need to be developed to overcome the related complications. |